Surgical treatment of mammary carcinomas in dogs with or without postoperative chemotherapy

Vet Comp Oncol. 2016 Sep;14(3):252-62. doi: 10.1111/vco.12092. Epub 2014 Apr 16.

Abstract

This retrospective study identified prognostic factors associated with survival; and compared survival data in 94 canine mammary carcinoma (MCA) dogs treated with surgery (n = 58), or surgery and adjunct chemotherapy (n = 36), and a subset of dogs with poor prognostic factors. On multivariate analysis independent predictors of median survival time (MST) were clinical stage, lymphatic invasion (LI; present 179 days; none 1098 days), ulceration (present 118 days; none 443 days) and surgical margins (incomplete 70 days; complete 872 days). Complete surgical margins were associated with MST in dogs with stages 1-3 MCA (incomplete 68 days; complete 1098 days) and dogs with LI (incomplete 70 days; complete 347 days). There was no statistically significant improvement in MST in dogs with advanced disease (stage 4 or LI) treated with adjunctive chemotherapy (chemotherapy 228 days; none 194 days); although five dogs with complete surgical margins that received mitoxantrone and carboplatin had a mean survival of 1139 days.

Keywords: cancer; canine; mammary cancer; mammary tumour; oncology; small animal.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma / pathology
  • Carcinoma / surgery
  • Carcinoma / veterinary*
  • Chemotherapy, Adjuvant / veterinary
  • Dog Diseases / drug therapy
  • Dog Diseases / pathology
  • Dog Diseases / surgery*
  • Dogs
  • Female
  • Mammary Neoplasms, Animal / pathology
  • Mammary Neoplasms, Animal / surgery*
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Antineoplastic Agents